We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02851797
Recruitment Status : Recruiting
First Posted : August 2, 2016
Last Update Posted : October 26, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

it is a randomised, double blind, parallel group, placebo controlled study. A total of 213 male ambulant subjects will be randomised 2:1 (givinostat:placebo).

Subjects will be stratified for their concomitant use of steroids in 4 strata:

  1. Deflazacort daily regimen
  2. Deflazacort intermittent regimen
  3. Other steroids daily regimen
  4. Other steroids intermittent regimen. The study duration is planned for 19 months.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: givinostat Drug: placebo Phase 3

Detailed Description:

Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses daily while the subject is in fed state, according to the child's weight.

Study drug should be permanently stopped if any of the following occur:

  • severe drug-related diarrhoea;
  • any drug-related Serious Adverse Event;
  • QTcF >500 msec;
  • platelets count ≤50 x 109/L.

Study drug should be temporarily stopped if any of the following occur:

  • platelets count <75 x 109/L but >50 x 109/L (the treatment should be temporarily stopped and a platelets count has to be performed and re-tested until platelets will be normalized);
  • moderate or severe diarrhoea.

In case the study drug was temporarily stopped, the study drug can be resumed at a level 1/3 smaller than the one at which the Adverse Event leading to temporary stop occurred, once platelets are normalized or diarrhoea is mild (if treatment was stopped for moderate or severe diarrhoea).

Two interim analyses are planned and will be conducted by the IDMC in order to ensure study integrity.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 213 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Actual Study Start Date : June 1, 2017
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Arms and Interventions

Arm Intervention/treatment
Active Comparator: givinostat
Givinostat oral suspension (10 mg/mL) twice daily in a fed state
Drug: givinostat
suspension of givinostat (10 mg/mL)
Placebo Comparator: placebo
Placebo oral suspension (10 mg/mL) twice daily in a fed state
Drug: placebo
suspension manufactured to mimic givinostat

Outcome Measures

Primary Outcome Measures :
  1. mean change in 4 standard stairs climb [ Time Frame: 18 months ]
    the primary endpoint is the mean change in 4 standard stairs climb test results before and after 18 months of treatment of givinostat versus placebo

Secondary Outcome Measures :
  1. Other functional test as 6MWT [ Time Frame: 18 months ]
    the mean change in 6MWT

  2. time to rise from floor [ Time Frame: 18 months ]
    the mean change in time to rise from floor

  3. Magnetic Resonance Spetroscopy [ Time Frame: 18 months ]
    the mean change in fat fraction of vastus lateralis muscles at MRS

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum creatinine kinase level) already present at screening;
  2. Have DMD diagnosis confirmed by genetic testing;
  3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations);
  4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results of these tests must be within ±1 second of each other;
  5. Have the mean of 2 screening 4SC assessments ≤8 seconds;
  6. Have time to rise from floor of <10 seconds at screening;
  7. Have manual muscle testing (MMT) of quadriceps at screening ≥ Grade 3;
  8. Are eligible according to the protocol-specified functional algorithm* predictive of vastus lateralis muscle fat fraction (VL MFF) that should be in the range >10% but <30% (see section 4.2.3);
  9. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the start of study treatment, with no significant change in dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study.

    • The protocol-specific functional algorithm will consider results relevant Four stairs climb test and knee extensor peak torque measurement.

Exclusion Criteria:

  1. Have exposure to another investigational drug within 3 months prior to the start of study treatment;
  2. Have exposure to idebenone within 3 months prior to the start of study treatment;
  3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping) within 6 months prior to the start of study treatment;
  4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed;
  5. Have surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study;
  6. Ankle joint contractures due to a fixed loss of ≥10 degrees of dorsiflexion from plantagrade assuming a normal range of dorsiflexion of 20 degree;
  7. Change in contracture treatment such as serial casting, contracture control devices, night splints, stretching exercises (passive, active, self) within 3 months prior to enrollment, or expected need for such intervention during the study;
  8. Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
  9. Have a diagnosis of other neurological diseases or presence of relevant somatic disorders that are not related to DMD;
  10. Have platelets count at screening < Lower Limit of Normal (LLN);
  11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class III or IV) or left ventricular ejection fraction <50% at screening;
  12. Have a current or history of liver disease or impairment;
  13. Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN);
  14. Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening;
  15. Have a baseline QTcF >450 msec, or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
  16. Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures;
  17. Have any known allergic reaction to givinostat or any of its excipients.

    For the subgroup of subjects who will undergo MRI and MRS (i.e., MR Cohort):

  18. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or seizure disorder).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02851797

Contact: Reference Study ID Number EPYDIS (DSC/14/2357/48) +39 026443 ext 2524 patientadvocacy@italfarmaco.com

  Hide Study Locations
United States, California
University of California - Davis Medical Center - Devis Physical Medicin & Rehabilitation Not yet recruiting
Davis, California, United States, 95817
Principal Investigator: Craig McDonald, MD         
David Geffen School of Medicine - UCLA Neurology Not yet recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Perry Shieh, MD         
Rady Children's Hospital center - UCSD Department of Neuroscience Not yet recruiting
San Diego, California, United States, 92123
Principal Investigator: Carla Grosmann, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Principal Investigator: Michele Yang, MD         
United States, Connecticut
Connecticut Children's Medical Center - Division Neurology Not yet recruiting
Hartford, Connecticut, United States, 06106
Principal Investigator: Gyula Acsadi, MD         
United States, Florida
Child Health Research Institute - Department of Pediatrics Not yet recruiting
Gainesville, Florida, United States, 32610
Principal Investigator: Barry Byrne, MD         
Nemours Children's Hospital Not yet recruiting
Orlando, Florida, United States, 32827
Principal Investigator: Richard Finkel, MD         
United States, Iowa
University of Iowa Children's Hospital Recruiting
Iowa City, Iowa, United States, 52242
Principal Investigator: Katherine Mathews, MD         
United States, Michigan
Wayne State University - University Pediatrics - Children's Hospital of Michigan Not yet recruiting
Detroit, Michigan, United States, 48201
Principal Investigator: Huiyuan Jiang, MD         
United States, Minnesota
University of Minnesota - Department of Neurology Not yet recruiting
Minneapolis, Minnesota, United States, 55455
Principal Investigator: Peter Manousakis, MD         
United States, Missouri
Washington University School of Medicine in St Louis - Department of Neurology Recruiting
Saint Louis, Missouri, United States, 63110
Principal Investigator: Anne Connolly, MD         
United States, Oregon
Shriners Hospitals for Children Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Erika Finanger, MD         
United States, Pennsylvania
The Children's Hospital of Philadelphia Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Gihan Tennekoon, MD         
United States, Virginia
Childrens Hospital of Richmond at Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23298
Principal Investigator: Jean Harper, MD         
University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology Recruiting
Leuven, Belgium, 03000
Principal Investigator: Nathalie Goemans, MD         
Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN) Not yet recruiting
Liege, Belgium, 04000
Principal Investigator: Laurent Servais, MD         
Canada, Alberta
Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada, T3B6A8
Principal Investigator: Jean Mah, MD         
Canada, British Columbia
The University of British Columbia, Children's and Womens Health Centre of BC Branch Not yet recruiting
Vancouver, British Columbia, Canada, V6H 3V4
Principal Investigator: Kathryn Selby, MD         
Canada, Ontario
Holland Bloorview Kids Rehabilitation Hospital Not yet recruiting
Toronto, Ontario, Canada, M4G1R8
Principal Investigator: Laura McAdam, MD         
CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest Recruiting
Nantes, France, 44093
Principal Investigator: Yann Pereon, MD         
Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques Recruiting
Paris, France, 75012
Principal Investigator: Teresa Gidaro, MD         
Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie Recruiting
Essen, Germany, 45122
Principal Investigator: Ulrike Schara, MD         
Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf Recruiting
Hamburg, Germany, 20246
Principal Investigator: Jessika Johanssen, MD         
Klinikum der Uniersitat Munchen - Campus Innenstadt Recruiting
Munchen, Germany, 80337
Principal Investigator: Wolfgang Muller-Felber, MD         
IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative Recruiting
Genova, Italy, 16147
Principal Investigator: Claudio Bruno, MD         
A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari Not yet recruiting
Messina, Italy, 98125
Principal Investigator: Giuseppe Vita, MD         
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica Recruiting
Milano, Italy, 20122
Principal Investigator: Giacomo Comi, MD         
Fondazione IRCCS Istituto Neurologico Carlo Besta Not yet recruiting
Milano, Italy, 20133
Principal Investigator: Giovanni Baranello, MD         
Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative Recruiting
Roma, Italy, 00146
Principal Investigator: Enrico Bertini, MD         
Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile Recruiting
Roma, Italy, 00168
Principal Investigator: Eugenio Mercuri, MD         
Leiden University Medical Center LUMC Recruiting
Leiden, Netherlands, ZH 2300 RC
Principal Investigator: Erik Niks, MD         
Radboud University Medical Centre Recruiting
Nijmegen, Netherlands, 6500
Principal Investigator: Imelda de Groot, MD         
Hospital Sant Joan de Déu - Neuromuscular Pathology Unit Recruiting
Esplugues de Llobregat, Barcelona, Spain, 08950
Principal Investigator: Andres Nascimento, MD         
Hospital Materno-Infantil - Passeig de la Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Principal Investigator: Francina Munell, MD         
Hospital 12 de Octubre - Hospital Materno Infantil Recruiting
Madrid, Spain, 28041
Principal Investigator: Ana Camacho Salas, MD         
Hospital Universitari i Politécnic de la Fe - Servicio Neurologia Recruiting
Valencia, Spain, 46026
Principal Investigator: Juan Jesus Vilchez, MD         
United Kingdom
Alder Hey Children's Hospital NHS Trust Not yet recruiting
Liverpool, United Kingdom, L12 2AP
Principal Investigator: Stefan Spinty, MD         
UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD Not yet recruiting
London, United Kingdom, EC1N 1EH
Principal Investigator: Francesco Muntoni, MD         
The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine Recruiting
Newcastle upon Tyne, United Kingdom, NE1 3BZ
Principal Investigator: Michela Guglieri, MD         
The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust Recruiting
Oswestry, United Kingdom, SY 10 7AG
Principal Investigator: Tracey Willis, MD         
Sponsors and Collaborators
inVentiv Health Clinical
More Information

Responsible Party: Italfarmaco
ClinicalTrials.gov Identifier: NCT02851797     History of Changes
Other Study ID Numbers: EPYDIS (DSC/14/2357/48)
First Posted: August 2, 2016    Key Record Dates
Last Update Posted: October 26, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked